20 October 2020 : Clinical Research
Use of Radiomics to Predict Response to Immunotherapy of Malignant Tumors of the Digestive System
Zhi Ji1BEF, Yong Cui2ABC, Zhi Peng1DEF, Jifang Gong1CE, Hai-tao Zhu2CD, Xiaotian Zhang1AE, Jian Li1CE, Ming Lu1CF, Zhihao Lu1AD, Lin Shen1AFG*, Ying-shi Sun2AFGDOI: 10.12659/MSM.924671
Med Sci Monit 2020; 26:e924671
Table 2 Demographic and clinical characteristics of patients treated with immunotherapy.
| Patients (N=112) | |
|---|---|
| Sex | |
| Male | 69 (71.1%) |
| Female | 28 (28.9%) |
| Location | |
| Stomach | 34 (35.1%) |
| Esophagus | 21 (21.6%) |
| Colorectum | 20 (20.6%) |
| Pancreas | 12 (12.4%) |
| Hepatobiliary | 8 (8.2%) |
| Intestine | 2 (2.1%) |
| Histological type | |
| Adenocarcinoma | 51 (52.6%) |
| Squamous carcinoma | 20 (20.6%) |
| Neuroendocrine carcinoma | 20 (20.6%) |
| Hepatocellular carcinoma | 4 (4.1%) |
| Cholangiocarcinoma | 2 (2.1%) |
| Radical operation | |
| No | 44 (45.4%) |
| Yes | 53 (54.6%) |
| Radiotherapy | |
| No | 69 (71.1%) |
| Yes | 28 (28.9%) |
| Targeted therapy | |
| No | 82 (84.5%) |
| Yes | 15 (15.5%) |
| ECOG performance status | |
| 0 | 48 (49.5%) |
| 1 | 49 (50.5%) |
| PD-L1 status | |
| Negative | 21 (42.0%) |
| Positive | 29 (58.0%) |
| MMR status | |
| pMMR | 37 (63.8%) |
| dMMR | 21 (36.2%) |
| Immunotherapy type | |
| PD-1 | 65 (67.0%) |
| PD-1+CTLA-4 | 3 (3.1%) |
| PD-L1 | 24 (24.7%) |
| PD-L1+CTLA-4 | 5 (5.2%) |
| ECOG – Eastern Cooperative Oncology Group; MMR – mismatch repair protein; pMMR – proficient MMR; dMMR – deficient MMR. | |